Anaphylaxis News and Research

RSS

Anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Due in part to the variety of definitions, between 1% and 15% of the population of the United States can be considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens. Of those people who actually experience anaphylaxis, up to 1% may die as a result.

Life-saving bone marrow transplants may also cure peanut allergies

Not only can bone marrow transplants be life-saving for children with acute lymphocytic leukemia, they may also cure peanut allergies. According to research presented during the American College of Allergy, Asthma and Immunology's Annual Scientific Meeting, a 10-year-old boy no longer had a peanut allergy after undergoing a bone marrow transplant.

8 Nov 2013

Oral allergy syndrome sufferers with hypertension may be at increased risk for severe reaction

Oral allergy syndrome sufferers that take high blood pressure medications may experience extreme facial swelling and difficulty breathing the next time they bite into a juicy apple.

8 Nov 2013

Anaphylaxis due to shrimp allergy is less than 8% in children

Anaphylaxis is a severe allergic reaction that can be life-threatening. Shellfish is the third most common food allergy to cause anaphylaxis.

8 Nov 2013

People with gelatin allergy can have reaction from flu vaccinations

Do marshmallows make your tongue swell? Gummy bears make you itchy? If you've answered yes and are allergic to gelatin, you will want to take some precautions when getting the flu shot.

8 Nov 2013

FDA approves Prior Approval Supplement for EMBEDA Extended Release Capsules CII

Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved a Prior Approval Supplement for EMBEDA (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII.

4 Nov 2013

Severe allergies in young people: an interview with Lynne Regent, CEO of Anaphylaxis Campaign

Around one third of the UK population – approximately 19 million people – will develop an allergy at some time in their lives. A significant proportion of these – around a million people – suffer severe symptoms.

17 Oct 2013

FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted and filed the company's supplemental Biologics License Application for subcutaneous use of Xolair (omalizumab) in people with Chronic Idiopathic Urticaria who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses.

11 Oct 2013

Halloween parties can heighten danger for kids with food allergies

The scary reality is that food allergies are becoming more and more common in the United States. In the past 10 years there has been an 18 percent increase in children with food allergies.

10 Oct 2013

Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

Amgen today announced that it will present data from several romosozumab and Prolia® (denosumab) studies at the American Society for Bone and Mineral Research (ASBMR) 2013 Annual Meeting in Baltimore from Oct. 4-7, 2013.

5 Oct 2013

New research shows no increased danger for egg allergic children who take flu shots

All children should have flu shots, even if they have an egg allergy, and it's now safe to get them without special precautions. This finding is from the latest update on the safety of the flu vaccine for allergic patients, published in the October issue of the Annals of Allergy, Asthma and Immunology, the official journal of the American College of Allergy, Asthma and Immunology.

2 Oct 2013

FDA grants accelerated approval to Perjeta for neoadjuvant treatment of breast cancer

The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer.

1 Oct 2013

University student shares experiences about managing severe allergy

Ahead of the first term back for university undergraduates this month, the Anaphylaxis Campaign has released a short film on their YouTube channel.

11 Sep 2013

Novartis starts shipment of 2013-2014 seasonal influenza vaccines to US customers

Novartis announced today that it has begun shipment of its seasonal influenza vaccines to customers in the US market for the 2013-2014 season. Novartis plans to ship a minimum of 30 million doses of its influenza vaccines to the US market, including Fluvirin (Influenza Virus Vaccine), approved for use in people 4 years of age and older, and Flucelvax (Influenza Virus Vaccine), approved for use in adults 18 years of age and older.

22 Aug 2013

Second GSK intramuscular quadrivalent influenza vaccine approved by the FDA

GlaxoSmithKline plc [LSE/NYSE: GSK] announced that the U.S. Food and Drug Administration (FDA) has approved FLULAVAL® QUADRIVALENT (Influenza Virus Vaccine) for the active immunization of persons three years of age and older to help prevent disease caused by seasonal influenza (flu) virus subtypes A and B contained in the vaccine.

19 Aug 2013

First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration for U.S. distribution and were shipped July 24.

25 Jul 2013

Symptoms, first-aid treatments and prevention tips for insect bites

Whether they are invading your picnic, hitching a ride on your skin or just buzzing around your head, bugs are an annoying and unavoidable part of summer. Still, there are times when bugs are just a nuisance and times when they can cause serious illness or injury.

24 Jul 2013

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Baxter International Inc. today announced data featuring ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method], a leading recombinant treatment available worldwide, during the 24th Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Amsterdam, The Netherlands.

From Baxter International Inc. 5 Jul 2013

Genentech's Perjeta regimen gets FDA Priority Review for HER2-positive early stage breast cancer

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application for the use of a Perjeta (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with HER2-positive early stage breast cancer.

2 Jul 2013

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.

24 Jun 2013

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).

20 Jun 2013

Anaphylaxis News and Research

Further Reading

Life-saving bone marrow transplants may also cure peanut allergies

Oral allergy syndrome sufferers with hypertension may be at increased risk for severe reaction

Anaphylaxis due to shrimp allergy is less than 8% in children

People with gelatin allergy can have reaction from flu vaccinations

FDA approves Prior Approval Supplement for EMBEDA Extended Release Capsules CII

Severe allergies in young people: an interview with Lynne Regent, CEO of Anaphylaxis Campaign

FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

Halloween parties can heighten danger for kids with food allergies

Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

New research shows no increased danger for egg allergic children who take flu shots

FDA grants accelerated approval to Perjeta for neoadjuvant treatment of breast cancer

University student shares experiences about managing severe allergy

Novartis starts shipment of 2013-2014 seasonal influenza vaccines to US customers

Second GSK intramuscular quadrivalent influenza vaccine approved by the FDA

First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

Symptoms, first-aid treatments and prevention tips for insect bites

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Genentech's Perjeta regimen gets FDA Priority Review for HER2-positive early stage breast cancer

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News